USFDA conducted a GMP surveillance inspection at Zydus Lifesciences' Unit 9 biologics facility in Ahmedabad from April 27 to May 5, 2026.
The inspection concluded with seven observations, though none were related to data integrity issues.
Zydus will work closely with the USFDA to address all observations expeditiously.
This disclosure is made pursuant to Regulation 30 of SEBI Listing Regulations.